All Type of News
“They need to understand International Nonproprietary Names is an international trend”
The Korean Pharmaceutical Association(President Chan-Hwi Cho, KPA) criticized the Korean Medical Association’s(KMA) argument about the ‘International Nonproprietary Names(INN)’ program was ‘implausible,’ and gave a cr...
Seoul Western DPO considers to start clinic S’s rebate investigation
The pharmaceutical field is getting nervous as the Seoul Western District Prosecutor’s Office(Seoul Western DPO), which has been quiet over pharmaceutical companies’ rebates, have shown movements to start a rebate inv...
Endless medicine manufacturing suspension and out of stock status
There have been an endless number of medicines with production suspension or temporarily going out of stock.
According to the industry concerned, Dong Wha Pharm’s ‘Flamotol Tab,’ Reyon Pharmaceutical’s ‘Opti-V Eye Dr...
Celltrion’s biosimilar ‘Herzuma’ proven in equivalence of efficacy with original
At the European Society for Medical Oncology(ESMO) symposium on the 9th(local time) in Madrid, Spain, Celltrion announced additional clinical trial results of 1-year safety of Herzuma(development name: CT-P6), an anti...
The amount of listed pharmas’ foreigner-owned stocks appraised is KRW 3.8 trillion
The amount of listed pharmaceutical companies’ stocks owned by foreign investors was appraised KRW 3.8 billion.
Yakup Shinmoon(www.yakup.com) analyzed the KOSPI and KOSDAQ listed pharmaceutical companies’ ratio of fo...
“International Nonproprietary Names(INN) is necessary for patient safety”
Greeting the FIP Seoul Congress, the International Pharmaceutical Federation(FIP) stressed that the International Nonproprietary Names(INN) are an international trend and told it was required for the government, pharm...
Distribution association’s ‘standby’ mode on negotiation for multinational pharma’s low margin policy
The pharmaceutical distribution industry has a stance that it is surely necessary to secure a level of proper margin to minimize various pressures, such as distribution margin cuts and an increase of SG&A(selling, gen...
Inist to jointly develop oral ‘bazedoxifene/cholecalciferol’ combination drug
Inist Bio Pharmaceutical(CEO Kook-Hyun Kim) will conduct an open innovation service of its product based on its know-hows as a CMO(contract manufacturing organization).
The company will open a briefing to suggest joi...
Boryung Pharm successfully hold Dukarb’s 1st anniversary symposium
Boryung Pharm(CEO Tae-Hong Choi) held a special symposium at Paradise City Hotel & Resort Incheon between the 9th and 10th to celebrate the Dukarb’s 1st release anniversary. Dukarb is a Kanarb/amlodipine combination m...
Rep. Mi-Hyuk Kwon tables a bill to adopt ‘class action system on foods and quasi drugs’
The Minjoo Party Rep. Mi-Hyuk Kwon tabled a partial revision bill to the Framework Act on Food Safety and the Pharmaceutical Affairs Law which contains articles about the ‘adoption of the class action system’ and the ...
